Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Q1 2025 value amounting to $2.0 million.

  • Lineage Cell Therapeutics' Change in Acquisitions & Divestments changed N/A to $2.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 6385.46%. This contributed to the annual value of $7.0 million for FY2024, which is 8894.68% down from last year.
  • According to the latest figures from Q1 2025, Lineage Cell Therapeutics' Change in Acquisitions & Divestments is $2.0 million.
  • Lineage Cell Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $24.3 million for Q2 2023, and its period low was $18000.0 during Q2 2024.
  • For the 3-year period, Lineage Cell Therapeutics' Change in Acquisitions & Divestments averaged around $9.0 million, with its median value being $4.9 million (2023).
  • The largest annual percentage gain for Lineage Cell Therapeutics' Change in Acquisitions & Divestments in the last 5 years was 3173.32% (2024), contrasted with its biggest fall of 9992.6% (2024).
  • Quarter analysis of 3 years shows Lineage Cell Therapeutics' Change in Acquisitions & Divestments stood at $9.8 million in 2023, then plummeted by 69.49% to $3.0 million in 2024, then crashed by 33.33% to $2.0 million in 2025.
  • Its Change in Acquisitions & Divestments was $2.0 million in Q1 2025, compared to $3.0 million in Q4 2024 and $4.0 million in Q3 2024.